ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
INNOSUISSE
Projektnummer
16640.1 PFLS-LS
Projekttitel
Identification and characterization of specific venom-derived peptides inhibiting the Tumour Necrosis Factor receptor 1: development of novel anti-inflammatory drug candidates
Projekttitel Englisch
Identification and characterization of specific venom-derived peptides inhibiting the Tumour Necrosis Factor receptor 1: development of novel anti-inflammatory drug candidates

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Kurzbeschreibung
Anzeigen
-
-
Anzeigen
Abstract
Anzeigen
-
-
Anzeigen

Erfasste Texte


KategorieText
Kurzbeschreibung
(Deutsch)
Identification and characterization of specific venom-derived peptides inhibiting the Tumour Necrosis Factor receptor 1: development of novel anti-inflammatory drug candidates
Kurzbeschreibung
(Englisch)
Identification and characterization of specific venom-derived peptides inhibiting the Tumour Necrosis Factor receptor 1: development of novel anti-inflammatory drug candidates
Abstract
(Deutsch)
Our objective is the discovery of venom peptides selectively inhibiting the binding of Tumor Necrosis Factor (TNF) to TNF receptor 1 (TNFR1) as anti-inflammatory drug candidates. Active venom extracts identified after screening of a library using a novel assay will be submitted to deconvolution. After purification, structural elucidation and synthesis of the best candidates, the most promising molecules will be characterized and their druggability potential will be assessed.
Abstract
(Englisch)
Our objective is the discovery of venom peptides selectively inhibiting the binding of Tumor Necrosis Factor (TNF) to TNF receptor 1 (TNFR1) as anti-inflammatory drug candidates. Active venom extracts identified after screening of a library using a novel assay will be submitted to deconvolution. After purification, structural elucidation and synthesis of the best candidates, the most promising molecules will be characterized and their druggability potential will be assessed.